MCMarley Cutrona

Marley Cutrona

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marley Cutrona has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • No New Safety Signals With Ruxolitinib Cream Used in Combination With Systemic Therapies for Atopic Dermatitis: A Multicenter Retrospective Study

    by Hibo Rijal, Neda Shahriari, Marley Cutrona, Christopher G. Bunick, E.JAmes Song, Peter Lio, Tina Bhutani-Jacques, Lindsay Ackerman, Jeffrey M. Cohen, Lisa Swanson, et al.

  • Open Access

    Acne therapy with isotretinoin is well tolerated in patients with established inflammatory bowel disease: a retrospective, single center study

    by Marley Cutrona, Ahuva Cices, Marla C Dubinsky, Elizabeth A Spencer

    Background: Early case reports and observational studies have suggested an association between isotretinoin and inflammatory bowel disease (IBD). However, large cohort studies and meta-analyses have not demonstrated a meaningful association between isotretinoin use and IBD development. Most prior research has focused on incident IBD risk, with limited attention to disease activity among patients with established IBD. Methods: We conducted a single-center retrospective cohort study of patients with Crohn’s disease (CD) or ulcerative colitis (UC) treated with isotretinoin between 2015 and 2025. Inclusion required at least 1 IBD assessment within the 4 months before and 12 months after isotretinoin initiation. Disease activity was assessed using Harvey–Bradshaw Index (HBI), partial Mayo score (pMS), inflammatory biomarkers, and in some patients, intestinal ultrasound and fecal calprotectin. The primary outcome was composite IBD status change, defined as new clinical activity (Δ ≥ 1 in HBI/pMS), or isotretinoin discontinuation attributed to IBD activity. Results: Thirty-seven patients met inclusion criteria (57% CD, 43% UC). Most patients were in clinical remission at baseline (86%). Following isotretinoin exposure, 92% remained in remission, with no significant changes in HBI, pMS, erythrocyte sedimentation rate, C-reactive protein, or fecal calprotectin. IBD status change occurred in 4 patients (11%), with events largely attributable to underlying IBD-related factors, including biologic transitions, anti-drug antibody development, or medication dose adjustments. Conclusions: Among patients with established, well-controlled IBD, isotretinoin was not associated with clinically meaningful worsening of disease activity, supporting its use in carefully selected patients with stable disease.

  • Residence‐Associated Differences in Airway Microbiology Among Tracheostomy‐Dependent Children

    by Elia D. Rackovsky, Marley Cutrona, Monica L. Koncicki, Brenda I. Anosike, Ilir Agalliu, Michelle M. Perez

    Background: Tracheostomy‐dependent children (TDC) experience chronic airway instrumentation and frequent healthcare exposure, increasing their risk for colonization and infection with multidrug‐resistant organisms (MDROs). Most TDC reside either in the community or in healthcare facilities, yet the impact of residential setting on airway microbiology in these children is not well characterized. Methods: We conducted a retrospective chart review of TDC ≤ 18 years admitted to an academic tertiary pediatric intensive care unit (PICU) between Jan 2017 and Dec 2022 who underwent tracheal aspirate cultures (TACs) within 72 h of admission. Airway microbiology and MDRO prevalence were compared between children presenting from healthcare facilities and the community. Multivariate mixed‐effect logistic regression models evaluated factors associated with MDRO isolation, adjusting for age, number of admissions, and cuffed tracheostomy status. Results: Among 109 children (282 admissions; 207 community, 75 facility), facility residence was associated with higher odds of isolating any MDROs in bivariate analysis (OR 2.73 95% CI 1.19–6.25 p = 0.017). In multivariate analysis, ≥ 5 prior hospital admissions and cuffed tracheostomy remained independently associated with MDRO isolation. Although facility residence no longer retained statistical significance after adjustment, the adjusted odds ratio remained similar to the bivariate estimate. Conclusions: Healthcare facility residence is associated with increased MDRO isolation. Cumulative healthcare exposure and cuffed tracheostomy status may also be important risk factors for MDRO presence. Respiratory microbiology differs between facility‐ and community‐based TDC. Awareness of local airway microbiologic patterns and cumulative healthcare exposure may improve interpretation of TACs and guide empiric antimicrobial therapy.

  • Open Access

    Roflumilast Cream for Residual Disease in Patients With Atopic Dermatitis on Dupilumab: A Retrospective Chart Review Study

    by Marley Cutrona, Alexandra K. Golant

    Introduction Residual disease is relatively common in dupilumab-treated patients with atopic dermatitis (AD). Adjunctive topical treatment, including topical corticosteroids or non-steroidal treatments, are often needed. In this study, we evaluated the clinical characteristics and outcomes of patients with AD on dupilumab with residual disease who were subsequently treated with roflumilast cream. Methods This was a retrospective chart review conducted at a single academic center. Electronic medical records were searched to identify patients with AD who were prescribed dupilumab and were subsequently prescribed roflumilast cream for persistent or residual disease between July 2022 and January 2026. Results Of the 676 cases of AD identified and included in this review, there were 30 cases of dupilumab-treated patients with residual AD disease. One additional patient with de novo facial erythema on dupilumab was described qualitatively. Following roflumilast cream treatment, physician-documented clinical improvement was reported in 83% (25/30) of these patients. Of 18 patients with patient-reported outcomes, ten reported improvement with roflumilast cream (including resolution of disease, near resolution, or significant improvement with decreased flares); five reported reduced pruritus (1 with fully resolved itch); three reported no improvement; and one discontinued roflumilast cream due to burning. No additional adverse events were documented in the medical records. Conclusions In this retrospective case series, adjunctive roflumilast cream was associated with physician-documented clinical improvement in most dupilumab-treated patients with residual AD.

  • Use of Oral JAK Inhibitors and a TYK2 Inhibitor in the Treatment of Psoriasis–Eczema Overlap ( PsEma ): A Retrospective Study

    by Marley Cutrona, Sophie Guénin, Mindy Kresch‐Vatch, Rabail Aslam, Emma Guttman‐Yassky, Mark Lebwohl, Alexandra K. Golant